Natera (NASDAQ:NTRA) Given New $405.00 Price Target at JPMorgan Chase & Co.

Natera (NASDAQ:NTRA) had its target price lowered by stock analysts at JPMorgan Chase & Co. from $460.00 to $405.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 30.36% from the stock’s previous close.

NTRA has been the subject of a number of other research reports. Guggenheim increased their target price on shares of Natera from $360.00 to $475.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Piper Sandler reaffirmed an “overweight” rating and issued a $363.50 price target on shares of Natera in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Thursday, October 15th. UBS Group upped their price target on Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Finally, Leerink Partners set a $330.00 price objective on Natera in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $391.69.

Natera Price Performance

Natera stock traded down $53.09 during trading hours on Friday, reaching $310.67. The stock had a trading volume of 5,775,589 shares, compared to its average volume of 1,457,838. The company has a market cap of $44.78 billion, a price-to-earnings ratio of -228.43 and a beta of 1.55. The business’s 50 day moving average price is $380.81 and its 200-day moving average price is $269.30. Natera has a 52 week low of $181.00 and a 52 week high of $437.41.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $793.98 million during the quarter, compared to the consensus estimate of $707.54 million. During the same quarter in the prior year, the business posted ($0.64) earnings per share. The firm’s quarterly revenue was up 34.1% on a year-over-year basis. On average, sell-side analysts forecast that Natera will post -1.14 EPS for the current fiscal year.

Insider Activity at Natera

In other Natera news, insider John Fesko sold 6,517 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the sale, the insider owned 197,257 shares of the company’s stock, valued at approximately $63,424,043.21. The trade was a 3.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 15,160 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the sale, the insider directly owned 110,859 shares in the company, valued at approximately $36,238,698.51. This represents a 12.03% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 53,573 shares of company stock worth $19,856,400. 5.05% of the stock is owned by insiders.

Institutional Investors Weigh In On Natera

Institutional investors and hedge funds have recently made changes to their positions in the stock. Trust Co. of Vermont purchased a new position in Natera in the 2nd quarter worth $26,000. Elevation Wealth Partners LLC purchased a new stake in Natera during the 2nd quarter valued at about $30,000. Continuum Advisory LLC purchased a new stake in Natera during the 2nd quarter valued at about $33,000. International Assets Investment Management LLC grew its stake in Natera by 132.9% during the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 97 shares during the last quarter. Finally, Rakuten Securities Inc. acquired a new position in shares of Natera in the second quarter valued at about $35,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Q3 revenue rose 34.1% year over year to $794 million, beating analyst expectations of about $708 million. Natera also raised its FY2026 sales outlook, supporting its growth outlook. Natera Q3 financial results
• Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could improve access to the test and support adoption of Natera’s oncology products. Medicare coverage for Signatera in HCC
• Negative Sentiment: CEO Steve Chapman is stepping down, creating uncertainty around leadership and the transition plan. The announcement weighed on sentiment despite the company’s revenue growth and improved outlook. Natera announces leadership transition
• Negative Sentiment: Natera’s quarterly loss narrowed from a year earlier, but its reported loss per share of $0.42 was worse than the analyst consensus of a $0.28 loss. That earnings miss appears to have overshadowed the revenue beat. Natera Q3 earnings miss and CEO transition

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.